For the quarter ending 2025-09-30, EVOK had -$483,062 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -1,156,208 | -2,877,154 |
| Stock-based compensation expense | 105,056 | 188,637 |
| Non-cash interest expense | 126,028 | 247,945 |
| Non-cash operating lease expense | 19,146 | 38,294 |
| Accounts receivable | 285,043 | 485,070 |
| Prepaid expenses and other assets | -154,688 | -571,766 |
| Inventories | -41,964 | 196,791 |
| Accounts payable and accrued expenses | 328,005 | 1,247,099 |
| Accrued compensation | 163,776 | -258,511 |
| Operating lease liabilities | -19,370 | -38,742 |
| Net cash used in operating activities | -521,958 | -1,562,527 |
| Proceeds from the issuance of common stock pursuant to the espp | 38,896 | 24,999 |
| Net cash provided by financing activities | 38,896 | 24,999 |
| Net (decrease) increase in cash and cash equivalents | -483,062 | -1,537,528 |
| Cash and cash equivalents at beginning of period | 13,596,600 | - |
| Cash and cash equivalents at end of period | 11,576,010 | - |
Evoke Pharma Inc (EVOK)
Evoke Pharma Inc (EVOK)